Literature DB >> 22446501

Natural killer cell immune escape in acute myeloid leukemia.

E Lion1, Y Willemen, Z N Berneman, V F I Van Tendeloo, E L J Smits.   

Abstract

As central players of the innate immune system, natural killer (NK) cells can exert direct and indirect anti-tumor effects via their cytotoxic and immune regulatory capacities, pivotal in the induction of an effective adaptive anti-tumor immune response. Hence, NK cells are considered to be important in the immune surveillance of cancer. In acute myeloid leukemia (AML) patients, however, significantly impaired NK cell functions can facilitate escape from immune surveillance and affect patient outcome. Here, we review various NK cell defects and AML evasion mechanisms to escape from NK cell-mediated immune surveillance and we discuss NK cell-related parameters as prediction factors of AML patient outcome. On the basis of these observations, novel immunotherapeutic strategies capitalizing on the potentiation of NK cell functions have emerged in AML immunotherapy, as discussed in this review. Increased knowledge on AML escape routes from NK cell immune surveillance will further aid in the design of novel NK cell-based immunotherapy approaches for the treatment of AML.

Entities:  

Mesh:

Year:  2012        PMID: 22446501     DOI: 10.1038/leu.2012.87

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  63 in total

1.  hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.

Authors:  Wen Jiang; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

2.  Circulating immune/inflammation markers in Chinese workers occupationally exposed to formaldehyde.

Authors:  Wei Jie Seow; Luoping Zhang; Roel Vermeulen; Xiaojiang Tang; Wei Hu; Bryan A Bassig; Zhiying Ji; Meredith S Shiels; Troy J Kemp; Min Shen; Chuangyi Qiu; Boris Reiss; Laura E Beane Freeman; Aaron Blair; Christopher Kim; Weihong Guo; Cuiju Wen; Laiyu Li; Ligia A Pinto; Hanlin Huang; Martyn T Smith; Allan Hildesheim; Nathaniel Rothman; Qing Lan
Journal:  Carcinogenesis       Date:  2015-04-23       Impact factor: 4.944

3.  The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.

Authors:  Magali Le Garff-Tavernier; Linda Herbi; Christophe de Romeuf; Nabih Azar; Damien Roos-Weil; Patrick Bonnemye; Rémi Urbain; Véronique Leblond; Hélène Merle-Beral; Vincent Vieillard
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

Review 4.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

Review 5.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

6.  The future of cellular immunotherapy for childhood leukemia.

Authors:  Challice L Bonifant; Sarah K Tasian
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

7.  The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Authors:  Alexander Hallner; Elin Bernson; Brwa Ali Hussein; Frida Ewald Sander; Mats Brune; Johan Aurelius; Anna Martner; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Blood       Date:  2019-01-15       Impact factor: 22.113

8.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

9.  Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance.

Authors:  Mingying Tang; Desmond Omane Acheampong; Youfu Wang; Wei Xie; Min Wang; Juan Zhang
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 10.  Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.

Authors:  Sébastien Anguille; Eva Lion; Johan Van den Bergh; Heleen H Van Acker; Yannick Willemen; Evelien L Smits; Viggo F Van Tendeloo; Zwi N Berneman
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.